

ONE HUNDRED SECOND LEGISLATURE - SECOND SESSION - 2012
COMMITTEE STATEMENT (CORRECTED)
LB814

Hearing Date: Thursday January 19, 2012
Committee On: Judiciary
Introducer: Schilz
One Liner: Include additional substances in the schedule of controlled substances under the Uniform Controlled Substances Act

Roll Call Vote - Final Committee Action:
Advanced to General File

Vote Results:

Aye: 8 Senators Ashford, Coash, Council, Harr, Larson, Lathrop, Lautenbaugh, McGill
Nay:
Absent:
Present Not Voting:

Proponents:

SEN. KEN SCHILZ
COREY O'BRIEN
CHRISTINE GABIG
MIKE VANCE
MARCIA MUETING

Representing:

INTRODUCER
ATTORNEY GENERAL'S OFFICE
DOUGLAS COUNTY SHERIFF
SEWARD COUNTY SHERIFF'S OFFICE
NE PHARMACIST ASSOCIATION

Opponents:

Representing:

Neutral:

Representing:

Summary of purpose and/or changes:

LB 814 is a bill that would make the following changes to Nebraska's Schedule of Controlled Substances:

Would classify any substance containing any quantity of the following materials , compounds, mixtures or structures as a schedule I drug:

3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;
3,4-methylenedioxypyrovalerone, or MDPV;
4-methylmethcathinone, or 4-MMC, or mephedrone;
4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;
Fluromethcathinone, or FMC;
Naphthylpyrovalerone, or naphyrone; or
Beta-keto-N-methylbenzodioxolylpropylamine; or

Subsection B, of section 36 is written to take into account the various substitutions that can be performed on the underlying substance. (Pages 13-14)

Would add Carisoprodol or any material, compound, mixture or preparation containing carisoprodol to the Nebraska Schedule of controlled Substances as a Schedule IV drug. (Page 30)

On page 31, removes, Pazo Hemorrhoidal Ointment as a schedule iv drug.

Would add the following substances to the Nebraska Schedule of Controlled Substances as a Schedule V drug:

Ezogabine [N- [2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester];

Lacosamide [(R) -2-acetomaido-N-benzyl-3-methoxy-propionamide]; and

Pregablin, [(S) -3- (aminomethyl) -5- methylhexanoicacid].

Brad Ashford, Chairperson